Carmustine

5 trials 2 recruiting LOncology

Filter these 5 trials by condition, phase, country and more.

Open in Search →

5 Registered trials

2 Recruiting

3 Completed trials

5 Sponsors

8 Countries

Phase III

Phase II

Phase III: 3 Phase II: 2

Indications tested

Diffuse large B-cell lymphoma 1 Mantle cell lymphoma stage IV 1 Mantle cell lymphoma stage III 1 Mantle cell lymphoma stage II 1 Relapsing-remitting multiple sclerosis 1 High-grade B-cell lymphoma 1 Primary mediastinal large B-cell lymphoma 1

Sponsors using this IMP

Fondazione Italiana Sclerosi Multipla Ente Del Terzo Settore/et S 1 Klinikum Der Landeshauptstadt Stuttgart gKAöR 1 Klinikum der Universitaet Muenchen AöR 1 Medical Center - University Of Freiburg 1 Novartis Pharma AG 1

All trials

5 total

CAR-T-cell treatment for untreated high risk MANtle Cell Lymphoma Recruiting

2022-502405-15-01 Phase II 5 countries Klinikum Der Universitat Munchen AöR
Age-adjusted high-dose chemotherapy followed by autologous stem cell transplantation or conventional chemotherapy with R-MP as first-line tr… Recruiting

2024-512320-11-00 Phase III 2 countries Medical Center - University Of Freiburg
Optimizing MATRix, a combination of Methotrexate, Ara-C, Thiotepa and Rituximab given as an induction therapy, de-escalated in duration and … Ended

2024-514473-21-00 Phase III 3 countries Klinikum Der Landeshauptstadt Stuttgart gKAöR
No Evidence Of Disease Activity After Autologous Haematopoietic Stem Cell Transplantation In Aggressive Multiple Sclerosis Ended

2024-515470-26-00 Phase II 1 country Fondazione Italiana Sclerosi Multipla Ente Del Terzo Settore/et S
Tisagenlecleucel in adult patients with aggressive B-cell non-Hodgkin lymphoma Ended

2023-508343-48-00 Phase III 7 countries Novartis Pharma AG

Showing 1–5 of 5 trials

← All drugs A–Z